XXXX - a Case Series of Oropharyngeal and Esophageal Primary Sites Treated with Chemo-Radiotherapy.

@entity1 @entity5 @entity4153
BACKGROUND: The optimal sequence and extent of multimodality therapy remains to be defined for @entity4153 because of its rarity. The purpose of our study was to assess the response to neoadjuvant chemotherapy followed by chemoradiation/radiation in @entity1 with @entity4153 . MATERIALS AND METHODS: Four consecutively diagnosed @entity1 were included in this study. The primary @entity5 site was oropharynx in three @entity1 and esophagus in one. The @entity1 with the limited disease were treated with chemotherapy followed by concurrent chemoradiation (n=2) or radiotherapy (n=1). The @entity1 with the extensive disease with the primary site in vallecula was treated with chemotherapy and palliative radiotherapy to the metastatic site. RESULTS: The median follow-up was 22.5 months (range, 8-24 months). Three @entity1 with the limited disease (base of tongue, n=2; esophagus, n=1) were in complete remission. The @entity1 with the extensive disease died of loco-regional @entity5 progression at 8 months from the time of diagnosis. CONCLUSIONS: The combination of chemotherapy and radiotherapy is the preferred therapeutic approach for @entity1 with @entity4153 . Induction chemotherapy followed by concurrent chemoradiation or radiation provides a good loco-regional control in @entity1 with limited disease.
